Payment overview · 2025
General Payments
$851.14
40 reported records · 19 companies
Healthcare provider profile · identity verified
William Lee Rowland, MD
Allopathic & Osteopathic Physicians|Family Medicine · BOCA RATON, FL · NPI 1639270200
Verified facts
What the public records show
CMS Open Payments records show William Lee Rowland, MD received $851.14 in general payments during 2025 across 40 reported records.
PFIZER INC. accounted for 24.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 29 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Jardiance, Mounjaro, Ozempic, Paxlovid.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 71 claims for Trulicity by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 183 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $209.78 | 24.6% | 6 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $145.31 | 17.1% | 9 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $79.55 | 9.3% | 4 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $53.48 | 6.3% | 3 | 2025 |
| Sonex Health, Inc. | Unresolved — no canonical attribution shown | $53.16 | 6.2% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $44.55 | 5.2% | 2 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $41.73 | 4.9% | 2 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $36.88 | 4.3% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $21.99 | 2.6% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $20.61 | 2.4% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $19.50 | 2.3% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $18.50 | 2.2% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $15.93 | 1.9% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $15.33 | 1.8% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $15.31 | 1.8% | 1 | 2025 |
| Hologic Sales and Service, LLC | Unresolved — no canonical attribution shown | $15.30 | 1.8% | 1 | 2025 |
| STRATA Skin Sciences, Inc. | Unresolved — no canonical attribution shown | $15.24 | 1.8% | 1 | 2025 |
| TMS NeuroHealth Centers Inc. | Unresolved — no canonical attribution shown | $15.14 | 1.8% | 1 | 2025 |
| Medicure Pharma Inc. | Unresolved — no canonical attribution shown | $13.85 | 1.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $851.14 | 40 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $184.31 | 4 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $145.31 | 9 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $145.31 | 9 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $59.34 | 3 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $53.98 | 3 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $53.48 | 3 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $53.48 | 3 | 2025 |
Source payment records
|
|||||
| SX-ONE MICROKNIFE Normalized: sx one microknife |
Device | Sonex Health, Inc. | $53.16 | 1 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $41.73 | 2 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $36.88 | 2 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $25.57 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $21.99 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $21.62 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $21.62 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $20.61 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $19.50 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $18.50 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $17.98 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $17.98 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $17.98 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $15.93 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $15.93 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $15.33 | 1 | 2025 |
Source payment records
|
|||||
| KEVEYIS Normalized: keveyis |
Drug | Xeris Pharmaceuticals, Inc. | $15.31 | 1 | 2025 |
Source payment records
|
|||||
| APTIMA Normalized: aptima |
Device | Hologic Sales and Service, LLC | $15.30 | 1 | 2025 |
Source payment records
|
|||||
| XTRAC Normalized: xtrac |
Device | STRATA Skin Sciences, Inc. | $15.24 | 1 | 2025 |
Source payment records
|
|||||
| TMS NeuroHealth Centers Inc. Normalized: tms neurohealth centers inc |
Device | TMS NeuroHealth Centers Inc. | $15.14 | 1 | 2025 |
Source payment records
|
|||||
| Zypitamag Normalized: zypitamag |
Drug | Medicure Pharma Inc. | $13.85 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $7.49 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 183 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 43 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 43 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 46 | exact normalized | Medicare Part D |
| PAXLOVID paxlovid |
2025 | Paxlovid | 2024 | 11 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
44 | 14 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
43 | 19 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
43 | 19 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
43 | 14 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
71 | 17 |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
46 | 16 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
183 | 50 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
11 | 11 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 852 | 292 |
| Atorvastatin Calcium | Atorvastatin Calcium | 824 | 301 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 736 | 295 |
| Levothyroxine Sodium | Levothyroxine Sodium | 608 | 193 |
| Lisinopril | Lisinopril | 449 | 167 |
| Losartan Potassium | Losartan Potassium | 419 | 162 |
| Metoprolol Succinate | Metoprolol Succinate | 381 | 146 |
| Metformin Hcl | Metformin Hcl | 378 | 131 |
| Alprazolam | Alprazolam | 245 | 96 |
| Tamsulosin Hcl | Tamsulosin Hcl | 216 | 85 |
| Omeprazole | Omeprazole | 212 | 89 |
| Pantoprazole Sodium | Pantoprazole Sodium | 212 | 86 |
| Zolpidem Tartrate | Zolpidem Tartrate | 202 | 64 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 190 | 67 |
| Eliquis | Apixaban | 183 | 50 |
| Ezetimibe | Ezetimibe | 167 | 66 |
| Atenolol | Atenolol | 165 | 53 |
| Quetiapine Fumarate | Quetiapine Fumarate | 153 | 71 |
| Hydrochlorothiazide | Hydrochlorothiazide | 151 | 62 |
| Carvedilol | Carvedilol | 138 | 47 |
| Simvastatin | Simvastatin | 121 | 49 |
| Trazodone Hcl | Trazodone Hcl | 117 | 61 |
| Prednisone | Prednisone | 113 | 68 |
| Metformin Hcl Er | Metformin Hcl | 109 | 50 |
| Allopurinol | Allopurinol | 105 | 46 |
| Spironolactone | Spironolactone | 104 | 38 |
| Sertraline Hcl | Sertraline Hcl | 103 | 47 |
| Escitalopram Oxalate | Escitalopram Oxalate | 100 | 43 |
| Furosemide | Furosemide | 93 | 41 |
| Famotidine | Famotidine | 91 | 47 |
| Azithromycin | Azithromycin | 89 | 72 |
| Finasteride | Finasteride | 88 | 32 |
| Pravastatin Sodium | Pravastatin Sodium | 88 | 27 |
| Gabapentin | Gabapentin | 79 | 36 |
| Glipizide Er | Glipizide | 77 | 26 |
| Mirtazapine | Mirtazapine | 77 | 45 |
| Potassium Chloride | Potassium Chloride | 72 | 31 |
| Clopidogrel | Clopidogrel Bisulfate | 71 | 25 |
| Trulicity | Dulaglutide | 71 | 17 |
| Lorazepam | Lorazepam | 70 | 23 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 69 | 27 |
| Synthroid | Levothyroxine Sodium | 65 | 21 |
| Metoprolol Tartrate | Metoprolol Tartrate | 62 | 21 |
| Propranolol Hcl | Propranolol Hcl | 60 | 23 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 57 | 19 |
| Montelukast Sodium | Montelukast Sodium | 57 | 24 |
| Valsartan | Valsartan | 57 | 20 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 56 | 19 |
| Pioglitazone Hcl | Pioglitazone Hcl | 56 | 23 |
| Bupropion Xl | Bupropion Hcl | 55 | 24 |
| Diazepam | Diazepam | 53 | 22 |
| Duloxetine Hcl | Duloxetine Hcl | 52 | 27 |
| Fluticasone Propionate | Fluticasone Propionate | 52 | 29 |
| Xarelto | Rivaroxaban | 51 | 19 |
| Alendronate Sodium | Alendronate Sodium | 47 | 17 |
| Glimepiride | Glimepiride | 46 | 12 |
| Ozempic | Semaglutide | 46 | 16 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 46 | 21 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 45 | 39 |
| Farxiga | Dapagliflozin Propanediol | 44 | 14 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 44 | 33 |
| Doxazosin Mesylate | Doxazosin Mesylate | 43 | 19 |
| Jardiance | Empagliflozin | 43 | 19 |
| Mounjaro | Tirzepatide | 43 | 14 |
| Warfarin Sodium | Warfarin Sodium | 42 | 11 |
| Clonazepam | Clonazepam | 39 | 22 |
| Mupirocin | Mupirocin | 39 | 26 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 39 | 12 |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 38 | 17 |
| Estradiol | Estradiol | 35 | 15 |
| Fluoxetine Hcl | Fluoxetine Hcl | 33 | 16 |
| Nifedipine Er | Nifedipine | 32 | 13 |
| Bumetanide | Bumetanide | 31 | 17 |
| Amoxicillin | Amoxicillin | 30 | 26 |
| Sildenafil Citrate | Sildenafil Citrate | 30 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 29 | 29 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 29 | 24 |
| Valacyclovir | Valacyclovir Hcl | 27 | 16 |
| Anastrozole | Anastrozole | 26 | 12 |
| Cefuroxime | Cefuroxime Axetil | 26 | 24 |
| Ipratropium Bromide | Ipratropium Bromide | 26 | 12 |
| Meloxicam | Meloxicam | 25 | 12 |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 25 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 23 | 11 |
| Doxycycline Hyclate | Doxycycline Hyclate | 23 | 23 |
| Eszopiclone | Eszopiclone | 23 | suppressed |
| Irbesartan | Irbesartan | 23 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 23 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 21 | suppressed |
| Cephalexin | Cephalexin | 21 | 14 |
| Temazepam | Temazepam | 21 | suppressed |
| Celecoxib | Celecoxib | 20 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 20 | 14 |
| Benazepril Hcl | Benazepril Hcl | 19 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 19 | suppressed |
| Levetiracetam | Levetiracetam | 19 | suppressed |
| Acyclovir | Acyclovir | 18 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 18 | 13 |
| Clonidine Hcl | Clonidine Hcl | 18 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 18 | 18 |
| Donepezil Hcl | Donepezil Hcl | 18 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 18 | suppressed |
| Dutasteride | Dutasteride | 18 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 18 | 13 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 18 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 17 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 17 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 16 | suppressed |
| Fenofibrate | Fenofibrate | 16 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 16 | 13 |
| Ondansetron Odt | Ondansetron | 16 | 14 |
| Terazosin Hcl | Terazosin Hcl | 16 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 15 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 15 | suppressed |
| Memantine Hcl | Memantine Hcl | 15 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 15 | 14 |
| Testosterone | Testosterone | 15 | suppressed |
| Fluorouracil | Fluorouracil | 14 | 13 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 14 | 11 |
| Myrbetriq | Mirabegron | 14 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 14 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 13 | suppressed |
| Hydrocortisone | Hydrocortisone | 13 | suppressed |
| Ketoconazole | Ketoconazole | 13 | 12 |
| Lovastatin | Lovastatin | 13 | suppressed |
| Progesterone | Progesterone, Micronized | 13 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 13 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 13 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 12 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 12 | suppressed |
| Entresto | Sacubitril/Valsartan | 12 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 12 | suppressed |
| Colchicine | Colchicine | 11 | suppressed |
| Ibuprofen | Ibuprofen | 11 | suppressed |
| Lamotrigine | Lamotrigine | 11 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 11 | 11 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 11 | suppressed |
| Verapamil Er | Verapamil Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $851.14 · 40 records | PFIZER INC. | ABRYSVO, AIRSUPRA, APTIMA, CAPVAXIVE, COMIRNATY, Cologuard Collection Kit, Dexcom G6 Transmitter, ELIQUIS, FREESTYLE LIBRE 3, GARDASIL 9, GEMTESA, JARDIANCE, KEVEYIS, LEQVIO, Leqembi, MOUNJARO, NURTEC ODT, OTEZLA, Ozempic, PAXLOVID, PREVNAR 20, REPATHA, Rybelsus, SX-ONE MICROKNIFE, TMS NeuroHealth Centers Inc., The Cologuard Plus Collection Kit, XTRAC, ZEPBOUND, Zypitamag | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error